Impact of CYP3A5/CYP2C19 Pharmacogenetics on Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation (HCT) Using Tacrolimus/Sirolimus (Tac/Sir) as Graft Versus Host Disease (GVHD) Prophylaxis

Samer K. Khaled, Ryotaro Nakamura, Joycelynne Palmer et al.|Transplantation and Cellular Therapy|2017

Cited by 0